Essential Thrombocythemia
Symptoms, Doctors, Treatments, Advances & More

Learn About Essential Thrombocythemia

What is the definition of Essential Thrombocythemia?

Essential thrombocythemia (ET) is a condition in which the bone marrow produces too many platelets. Platelets are particles in the blood that aid in blood clotting.

What are the alternative names for Essential Thrombocythemia?

Primary thrombocythemia; Essential thrombocytosis

What are the causes of Essential Thrombocythemia?

ET results in an overproduction of platelets. The higher number of platelets may increase the risk of clotting. However, bleeding may occur with very high platelet count because blood clots use up the body's platelets. Untreated, ET worsens over time.

ET is part of a group of conditions known as myeloproliferative disorders. Others include:

  • Chronic myelogenous leukemia (an overproduction of white blood cells that starts in the bone marrow)
  • Polycythemia vera (bone marrow disease that leads to an abnormal increase in the number of red blood cells)
  • Primary myelofibrosis (disorder of the bone marrow in which the marrow is replaced by fibrous scar tissue)

Many people with ET have a variation of a gene (JAK2, CALR, or MPL).

ET is most common in middle- to older-age people. It can also sometimes be seen in younger people, especially women.

What are the symptoms of Essential Thrombocythemia?

Symptoms may include any of the following:

  • Headache
  • Tingling, coldness, or blueness in the hands and feet
  • Feeling dizzy or lightheaded
  • Vision problems
  • Mini-strokes (transient ischemic attacks) or stroke

If bleeding is a problem, symptoms may include any of the following:

  • Easy bruising and nosebleeds
  • Bleeding from the gastrointestinal tract, respiratory system, urinary tract, or skin
  • Bleeding from the gums
  • Prolonged bleeding from surgical procedures or tooth removal
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Essential Thrombocythemia?

If you have life-threatening complications, you may have a treatment called platelet pheresis. It quickly reduces the number of platelets in the blood.

Long-term, medicines are used to decrease the platelet count to avoid complications. The most common medicines used include hydroxyurea, interferon-alpha, or anagrelide.

Aspirin at a low dose (81 to 100 mg once or twice per day) may decrease clotting episodes.

Many people do not need any treatment, but they must be followed closely by their health care provider.

Who are the top Essential Thrombocythemia Local Doctors?
Elite in Essential Thrombocythemia
Hematology | Oncology
Elite in Essential Thrombocythemia
Hematology | Oncology
Referral required

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mesa is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is board certified in American Board Of Internal Medicine, Hematology. Dr. Mesa is currently accepting new patients.

Elite in Essential Thrombocythemia
Elite in Essential Thrombocythemia
Referral may be required
Rome, IT 

Mario Cazzola practices practicing medicine in Rome, Italy. Mr. Cazzola is rated as an Elite expert by MediFind in the treatment of Essential Thrombocythemia. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Chronic Obstructive Pulmonary Disease (COPD), Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Essential Thrombocythemia
Elite in Essential Thrombocythemia
Referral may be required

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
Languages Spoken:
English, Arabic
Accepting New Patients
Offers Telehealth

Abdulraheem Yacoub is a Hematologist practicing medicine in Fairway, Kansas. Dr. Yacoub is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. He is also highly rated in 51 other conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Yacoub is board certified in American Board Of Internal Medicine, Hematology - 2012 and American Board Of Internal Medicine, Medical Oncology - 2011. Dr. Yacoub is currently accepting new patients.

What is the outlook (prognosis) for Essential Thrombocythemia?

Outcomes may vary. Most people can go for long periods without complications and have a normal lifespan. In a small number of people, complications from bleeding and blood clots can cause serious problems.

In rare cases, the disease can change into acute leukemia or myelofibrosis.

What are the possible complications of Essential Thrombocythemia?

Complications may include:

  • Acute leukemia or myelofibrosis
  • Severe bleeding (hemorrhage)
  • Stroke, heart attack, or blood clots
When should I contact a medical professional for Essential Thrombocythemia?

Contact your provider if:

  • You have unexplained bleeding that continues longer than it should.
  • You notice chest pain, leg pain, confusion, weakness, numbness, or other new symptoms.
What are the latest Essential Thrombocythemia Clinical Trials?
A Phase I Study of Ruxolitinib Plus Abemaciclib for Patients With Primary or Post-polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Summary: The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis

Summary: This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\[s\]). The study consists of a dose-escalation phase followed ...

What are the Latest Advances for Essential Thrombocythemia?
Who are the sources who wrote this article ?

Published Date: February 03, 2025
Published By: Warren Brenner, MD, Oncologist, Lynn Cancer Institute, Boca Raton, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Gotlib J. Polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 152.

Marcellino BK, Mascarenhas J, Iancu-Rubin C, Kremyanskaya M, Najfeld V, Hoffman R. Essential thrombocythemia. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 71.

National Cancer Institute website. Myeloproliferative neoplasms treatment (PDQ) -- health professional version. www.cancer.gov/types/myeloproliferative/hp/myeloproliferative-neoplasms-treatment. Updated September 27, 2024. Accessed February 11, 2025.